Jérémie Calais, MD, PhDAdvanced Imaging | February 15, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
View More
Emily MenendezLocalized | February 15, 2024
Radical prostatectomy resulted in worse urinary incontinence for patients with localized prostate cancer.
Scott Eggener, MDASCO GU Symposium 2024 | January 30, 2024
Dr. Eggener describes the Stockholm3 test and reasons for validating it in an ethnically-diverse population.
Emily MenendezLocalized | January 8, 2024
No G3 or G4 GU or GI toxicities occurred in either treatment arm, and G2 toxicities were uncommon.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis continue their EMBARK discussions and recommendations for treating high-risk BCR prostate cancer.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis discuss the details of the NEJM phase 3 EMBARK study on enzalutamide in BCR prostate cancer.
David Ambinder, MDLocalized | December 4, 2023
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | February 8, 2024
Drs. George and Wallis discuss applications and counseling patients on focal therapy, as well as post-treatment follow-up.
Emily MenendezSUO 2023 | December 18, 2023
Enzalutamide plus leuprolide acetate and enzalutamide alone caused delayed MFS when compared with placebo plus leuprolide.
Zachary BessetteLocalized | November 17, 2023
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
Emily MenendezLocalized | November 10, 2023
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
Zachary BessetteAdvanced Imaging | November 7, 2023
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Katy MarshallLocalized | October 27, 2023
Enzalutamide combined with leuprolide led to higher rates of MFS than leuprolide alone.
Zachary BessetteESMO 2023 | October 18, 2023
ArteraAI Prostate—a multimodal, AI-derived prognostic test—was successfully validated in the phase 3 STAMPEDE trials.
Zachary BessetteESMO 2023 | October 18, 2023
New understandings of PROs related to enzalutamide-plus-leuprolide-acetate treatment for high-risk BCR nmHSPC.
Emily MenendezASTRO 2023 | October 6, 2023
According to new data, concerns surrounding the efficacy of 19-20 Gy single-dose HDR-BT as a monotherapy may be unfounded.
Emily MenendezASTRO 2023 | October 3, 2023
While the low-dose arm required more salvage therapy, dose-escalated RT resulted in lower rates of DM.
Zachary BessetteASTRO 2023 | October 2, 2023
Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC.